NCT Number: NCT07178652
The IMMUN-OR study aims to study HLA-C/KIR combinations when looking at the risk of development of preeclampsia (PE) in pregnancies after oocyte donation. With the use of oocyte donation currently on the rise, the importance of identifying risk factors for the higher frequency of PE development is clear. Certain HLA-C/KIR combinations have already been linked to higher risk of obstetric complications. This study will look at these combinations within the specific situation of oocyte donation. This will further investigate the importance of the immunological interface when looking at PE. Participants will be chosen from a database of all the live births after oocyte donation at our center. The research team will contact the mother, child and donor. If all three agree to participate, they will be invited to our center, where the research team will take a cheek swab. This swab will then be used to isolate a DNA sample. With these samples, we can determine the HLA-C/KIR combination for each threesome. When all samples have been collected, two groups are made based off their health outcome: one group that did develop PE during their pregnancy, and one group that did not develop PE. The different HLA-C/KIR combinations will be compared, and the research team will look to discover if one combination is linked to a higher occurrence of PE development.
Trial opening soon.
Get NotifiedFemale
Observational
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: From 20 weeks gestation until 6 weeks postpartum.
The development of PE throughout the pregnancy conceived through oocyte donation.
Time frame: From 20 weeks gestation until 6 weeks postpartum in pregnancies conceived through oocyte donation.
The development of PE before 34 weeks gestation (= early onset PE) or after 34 weeks of gestation (= late onset PE).
Time frame: From 20 weeks gestation until 6 weeks postpartum in pregnancies conceived through oocyte donation.
Development of preterm PE (<37 weeks gestation), term PE (>37 weeks gestation) and postpartum PE (after birth) throughout a pregnancy conceived through oocyte donation.
Time frame: From conception until 6 weeks postpartum in pregnancies conceived through oocyte donation.
The occurence of eclampsia, placental abruption and HELLP syndrome in pregnancies conceived through oocyte donation.
Time frame: From conceptions until birth in pregnancies conceived through oocyte donation.
Incidence of obstetrical complications such as gestational hypertension, IUGR, PPROM, ...
Time frame: From conception until birth in pregnancies conceived through oocyte donation.
Details about delivery such as preterm birth, the incidence and indication for caesarean sections, neonatal birth weights, neonatal birth defects, neonatal complications, ...
Universitair Ziekenhuis Brussel
Other
Acronym: IMMUN-OR
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07479329
Autoimmune Diseases, Cardiovascular Diseases
Barcelona, Spain
View Trial DetailsNCT07463898
Cardiovascular Biomarkers, Female Urogenital Diseases and Pregnancy Complications
Abuja, Nigeria
View Trial DetailsNCT07565727
Cardiometabolic Diseases, Diabetes Mellitus
Knoxville, Tennessee, United States
View Trial DetailsNCT06802861
Body Weight, Diabetes Mellitus
Knoxville, Tennessee, United States
View Trial Details